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This review outlines briefly the history and present status ofthe problem ofcarcinogenic, teratogenic
and mutagenic effects of arsenic. Discrepancies between dinical observations and positive results of
epidemiological studies and the experimental induction of cancer by arsenic are discussed. The present
knowledge of the mechanism of teratogenic and mutagenic effects of arsenic is analyzed.
The growing importance of arsenic as an environmental pollutant is demonstrated. Continuation of
throughly organized epidemiological studies in regions with excessive arsenic exposure ofthe population
and standardization ofan epidemiological approach to this problem on an international basis are recom-
mended. New approaches in experimental studies of the carcinogenicity of arsenic in combination with
other known or suspected carcinogens are recommended as well.
Arsenic has long been thought to contribute to
the incidence of cancer. In connection with the
growing number of people exposed to this sub-
stance, occupationally as well as nonoccu-
pationally in some areas, this becomes an im-
portant problem. The aim ofthis paper is to outline
the history and present state ofthis problem and its
possible solution. Some remarks concerning the
mutagenic and teratogenic effects ofarsenic are of-
fered as well.
The occurrence of scrotal carcinoma among cop-
per smelter workers in Cornwall (Wales) was de-
scribed as early as 1820 by Paris (1), who regarded
it as a consequence of exposure to arsenic fumes.
Wilson (18%) noticed a relationship between multi-
ple hyperkeratoses and arsenic exposure. Skin car-
cinomas occurring after long-term treatment with
arsenic preparations were described by Hutchinson
(2). A common feature ofthese carcinomas was the
previous occurrence of multiple keratoses. Geyer
(1898) described 65 skin carcinomas in Cordoba,
where the contamination ofdrinking water by arse-
nic reached 0.45 mg As/l. (3). Lung carcinomas
among miners at the Schneeberg mine were attrib-
uted to the arsenic in mine dust, its concentrations
being about 1% (4), until 1932, when Pirchan and
Sikl considered that this carcinoma might result
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from the radioactivity of the mind ores (5). It is
possible that both agents contribute. The tendency
of arsenical hyperkeratoses toward malignant de-
generation was analyzed in a group of several
hundred patients, with the resulting conclusion that
at least 20% suffered from malignant disease (6).
Neubauer (7) reviewed 143 published cases, of
which 71% presented multiple carcinomas com-
bined with a history of arsenic exposure; he re-
marked, however that in many cases other possible
contributory factors were present. Cerny and
Neuman (8) demonstrated a highly suspicious rela-
tionship between arsenic and skin carcinoma.
Neuman and Schwank (9) published considerable
material which points irrefutably to arsenic as a
causative factor in multiple keratoses and skin car-
cinomas. These authors stressed the needless risk
ofprescribing frequently useless arsenical drugs. In
their collection of patients, the latency from initia-
tion of treatment with arsenicals to the occurrence
of carcinoma was in most cases more than 20 yr
and, in one third of examined cases, more than 30
yr. These values correspond to those found in most
ofthe literature. Chronic arsenic exposure has been
implicated in the pathogenesis of angiosarcoma in
German vineyard workers (10). Long-term medical
administration of arsenic in the form of Fowler's
solution has been implicated in two cases of an-
giosarcoma to date (11, 12). The suspicion that ar-
senic can cause malignant degeneration of cells is
the reason for which several authors stress the
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human therapy. Such a prohibition is now in effect,
e.g., in Czechoslovakia, where the use of arsenic
preparations in human therapy is forbidden, with
the exception of those applied in the treatment of
protozoal infections.
Cancers of probable occupational origin have
been reported in gardeners (13) and in vineyard
workers (14, 15); in both cases, arsenic exposure
was through the use of arsenical pesticides. The
long-term mortality analysis in workers handling
organic compounds of arsenic showed a higher in-
cidence of carcinomas compared to the local popu-
lation (16, 17). Workers who handled arsenicals ex-
hibited marked pigmentations and hyperkeratoses
with wartlike growths on exposed areas, and ele-
vated arsenic levels in urine and hair. At the time of
examination no arsenic-related cancer was found.
Snegireff and Lombard (18) compared cancer inci-
dence rates between factory workers with and
without arsenic exposure. In spite of the evidence
for the carcinogenicity of. arsenic, there were no
statistically significant conclusions, possibly be-
cause the examined groups were relatively small.
Papers were published which demonstrated cases
of carcinomas of internal organs after arsenic ex-
posure (19-28). Recently (29) carefully performed
epidemiological studies clearly demonstrate the
likelihood of arsenic being carcinogenic.
Until recently, experimental attempts to induce
"arsenical" carcinomas in animals either failed or
were of very limited significance (30-32). Askanazi
(33) noticed benign and malignant teratomas in rat
embryos transplanted into the peritoneal cavity of
rats whose drinking water contained arsenic. Em-
bryonal cells are especially sensitive to arsenic
which provoked in them signs ofdegeneration even
in concentrations of 0.25 ,tg/l. of cultivation
medium (34). Repeated, long-term treatment ofthe
skin of white mice with an 18% solution of sodium
arsenate induces squamous cell carcinoma. With
oral administration, this phenomenon is not ob-
served (35).
The results of the experiments do not seem to be
a simple confirmation of clinical experience, espe-
cially when we consider the carcinomas ofinternal
organs after arsenic exposure. It should be stated
however that in view of the very long latency of
arsenical carcinomas observed clinically, the ani-
mal experiments were hardly comparable. It was
found that arsenic causes fragmentation and recon-
struction of chromosomes during mitosis, thus
causing either mutation or cell death. This
"colchicine-type" effect is the mechanism on which
arsenic treatment ofhemoblastosis was based. Clin-
ical experience argued for the possibility that arse-
nic works as a carcinogen primarily in pathologi-
cally altered terrain-skin hyperkeraroses, cirrhotic
liver, (vineyards) chronic bronchitis from industrial
irritants, and so on. Nevertheless, activation
analysis of epitheliomas has shown smaller quan-
tities ofarsenic in the epitheliomas themselves than
in the neighboring healthy skin (36). It is well
known, however, that substances with delayed ef-
fects, e.g., beryllium, are notpresentin the affected
tissue in important quantities at the time pathologi-
cal changes manifest themselves.
Teratogenic effects have been ascribed to arsenic
as well. Its teratogenicity was demonstrated in
golden hamsters (37, 38), in mice (39), and in rats
(40). The four most frequently seen soft tissue mal-
formations were eye defects (anophtalmia and mic-
rophtalmia), exencephaly, renal and godonal
ageneses. Ribs and vertebrae were the skeletal ele-
ments most susceptible to arsenic treatment. When
introduced into fertilized bird eggs, arsenic causes
beak and brain malformations (41).
At the end ofchronic exposure ofmice to arsenic
in drinking water (50 ppm), we found the germinal
epithelium ofthe testes considerably damaged (42).
Possible genetic risks from arsenic exposure have
been indicated in experiments which demonstrated
the ability of inorganic arsenicals to provoke
chromosomal aberrations in human lymphocytes in
vitro (43, 44). Cell division defects and increased
frequency of chromosomal abnormalities were
found in patients treated with arsenic-containing
drugs over long periods of time (45). Arsenic in
combination with the referential mutagen
[chemosterilantTEPA, tris (1-aziridinyl) phosphine
oxide] provoked a significant increase in dominant
lethal mutations in mice of the F3 generation. The
probable explanationofthis phenomenon, observed
only at higher exposure rates, is that arsenic dam-
ages the natural mechanism ofchromosome repair,
e.g., by blocking SH groups which play an impor-
tant role in enzymes involved in such repair (46).
Several studies performed heretofore demon-
strate also nonoccupational environmental as well
as occupational exposure ofpopulations ofdifferent
regions to arsenic (28, 29, 47-50). In view of this
fact, it seems reasonable to continue thoroughly or-
ganized epidemiological studies in regions ofexces-
sive arsenic exposure to study the question of the
carcinogenicity of this substance. To obtain com-
parable results it may be useful to standardize the
epidemiological approach to this problem on an in-
ternational basis, which would be a task for WHO.
The inconclusive results of past experiments in
arsenic carcinogenicity certainly do notjustify cur-
Environmental Health Perspectives 180tailing this research. New approaches, such as
perhaps the combination of arsenic with other
known or suspected carcinogens, may be ofvalue.
This review was compilated during the author's WHO fellow-
ship stay at the Department of Environmental Hygiene, the
Karolinska Institute in Stockholm. The author gratefully ack-
nowledges the encouraging interest of Professor Lars Friberg,
who initiated this work.
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